Cardiovascular

Reversible ADP Antagonists: New Alternatives To Clopidogrel For Anti-Platelet Therapy In Elective PCI

November 24, 2009
Deepak Bhatt

Deepak Bhatt

ORLANDO—Deepak Bhatt from the VA Boston Healthcare System and Brigham & Women’s Hospital, talks with Peter Goodwin about findings from the CHAMPION-PLATFORM study (using cangrelor in PCI) and the PLATO study (with ticagrelor in ACS)—testing reversible ADP antagonist agents as anti-platelet therapy, as reported at the American Heart Association Annual Meeting held in Orlando.

Download this interview

Add podcast to iTunes

Similar Interviews

  • Warfarin Trumps Platelet Agents in Atrial Fibrilation

    • For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin

  • Chronic Stable Angina: Should ESC Guidelines on Clopidogrel as Pre-Treatment to Planned Coronary Angiography be Changed?

  • CHARISMA Trial: Add Clopidogrel to Aspirin? Not for Lower Risk Patients

    • Deepak Bhatt, Cleveland Clinic, Ohio American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The idea of adding clopidogrel anti-platelet

    Post a comment